查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1736743

全球视神经疾病治疗市场规模（按治疗类型、神经系统疾病类型、最终用户、区域范围和预测）

Global Optic Nerve Disorders Treatment Market Size By Type of Treatment (Eye Drops, Steroids), By Type of Nerve Disorder (Glaucoma, Optic neuritis), By End User (Hospitals, Ophthalmology Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

视神经疾病治疗市场规模及预测

2024 年视神经疾病治疗市场规模价值 36 亿美元，预计到 2032 年将达到 57 亿美元，预测期内（2026-2032 年）的复合年增长率为 4.7%。

视神经疾病是指视神经（一组负责将视觉讯息从眼睛传递到大脑的神经纤维）因发炎（肿胀）而受损的疾病。视神经疾病的特征是单眼暂时性视力丧失和眼球运动时不适。由于视神经疾病盛行率的上升、久坐生活方式的改变以及糖尿病、高血压等文明病发病率的上升，预计全球视神经疾病治疗市场在预测期内将持续增长。本研究报告对全球视神经疾病治疗市场进行了全面评估。

定义视神经疾病治疗的全球市场

连接视网膜细胞和视交叉的脑神经称为视神经。视网膜的感光细胞捕捉光线，并透过视神经向大脑发送电脉衝。视神经功能障碍或损伤可能导致视力丧失，这取决于病变的类型和位置。视力问题可能发生在一隻眼睛或两隻眼睛。电讯号从视网膜的感光细胞经由视神经传送到大脑的视觉皮质。

视神经或其路径的任何损伤都可能导致永久性眼损伤和视力丧失。视神经疾病是最常见的视神经损伤疾病之一。视神经因髓鞘（覆盖视神经的保护膜）的损伤或缺失而发炎。研究人员表示，髓鞘的发炎和破坏可导致视神经疾病。视神经和视交叉在视交叉处交汇，扮演重要角色。

当视神经分裂成两个部分时，两侧各有一半的神经纤维会交叉到另一侧。神经损伤或神经保护膜的去除都会导致神经发炎。视神经疾病包括青光眼、视神经疾病、视神经萎缩症和视盘视网膜黄斑硬化症 (ODD)。治疗方案包括皮质类固醇、静脉注射免疫球蛋白 (IVIG)/血浆置换、维生素 B12 注射和手术，取决于疾病的程度和类型。

全球视神经疾病治疗市场概况

根据世界卫生组织统计，2019年全球22亿人视力受损或失明。其中，白内障、未矫正的屈光不正、青光眼和角膜混浊是视力受损的主要原因。青光眼是导致眼内压升高和视神经疾病恶化的主要因素之一。青光眼也可能由感染疾病和化学性眼科疾病疾病引起，但它通常是遗传性疾病。早期发现和早期治疗的方法包括眼药水、口服药物和雷射治疗。

多发性硬化症 (MS) 是一种自体免疫疾病，免疫系统会攻击体内的健康细胞，是视神经疾病的主要原因。由于免疫力下降，MS 在高龄化社会中更为普遍，也可能由糖尿病、吸烟和感染疾病引起。由于久坐不动的生活方式、不良饮食和缺乏运动，糖尿病、高血压和高血压等文明病率呈上升趋势，这使得 MS 更容易引起眼神经炎。因此，需要治疗这种疾病的人数比例正在增加。类固醇通常用于治疗视神经疾病并防止症状恶化。

虽然视神经疾病尚无根治治疗方法，但人们重视预防和早期发现，以避免药物治疗、药物和手术带来的併发症。老龄人口的成长以及人们日益意识到早期诊断以阻止症状恶化的重要性，推动了对视神经疾病治疗和手术的需求，从而支撑了此类治疗市场的成长。然而，青光眼等视神经疾病治疗的潜在副作用（例如眼睛颜色改变、眼窝凹陷、搔痒等）阻碍了市场的扩张。

目录

第一章全球视神经疾病治疗市集简介

  • 市场概览
  • 研究范围
  • 先决条件

第 2 章 已验证的市场研究调查方法

  • 资料探勘
  • 二次研究
  • 初步研究
  • 专家建议
  • 品质检查
  • 最终审核
  • 数据三角测量
  • 自下而上的方法
  • 自上而下的方法
  • 调查流程
  • 资料来源

第三章执行摘要

  • 概述
  • 绝对的商机
  • 市场吸引力
  • 未来市场机会

第四章视神经疾病治疗的全球市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章 全球视神经疾病治疗市场（依治疗类型）

  • 概述
  • 眼药水
  • 类固醇
  • 静脉注射免疫球蛋白/血浆置换
  • 维生素B12注射剂
  • 外科手术

第六章 全球视神经疾病治疗市场（依神经系统疾病类型）

  • 概述
  • 青光眼
  • 视神经疾病
  • 其他的

第七章全球视神经疾病治疗市场（依最终使用者）

  • 概述
  • 医院
  • 眼科诊所
  • 门诊手术中心

第八章全球视神经疾病治疗市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

第九章全球视神经疾病治疗市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略
  • 公司地理分布
  • 公司在各行业的足迹
  • ACE矩阵

第十章 公司简介

  • Bionure Farma SL
  • Teva Pharmaceutical Industries
  • Santen Pharmaceutical
  • Novartis AG
  • Pfizer
  • Allergan
  • Aerie Pharmaceuticals
  • Mallinckrodt Pharmaceuticals
  • Merck Sharp & Dohme Corp
  • Bausch Health Companies

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 40550

Optic Nerve Disorders Treatment Market Size And Forecast

Optic Nerve Disorders Treatment Market size was valued at USD 3.6 Billion in 2024 and is projected to reach USD 5.7 Billion by 2032, growing at a CAGR of 4.7% during the forecast period 2026-2032.

Optic neuritis is a condition in which the optic nerve, a group of nerve fibers that transmits visual information from the eye to the brain, is destroyed by inflammation (swelling). Optic neuritis is characterized by temporary vision loss in one eye and discomfort with eye movement. Due to the rising prevalence of optic illnesses, the adoption of a sedentary lifestyle, and the rising incidence of lifestyle diseases like diabetes, Blood Pressure & Hypertension, the global market for treatments for optic nerve disorders is anticipated to grow over the course of the forecasted period. The market is comprehensively evaluated in the study on the global market for treating optic nerve disorders.

Global Optic Nerve Disorders Treatment Market Definition

The cranial nerves that connect the retinal cells to the optic chiasm are known as the optic nerves. The retina's photoreceptor cells take in light and send electric impulses to the brain through the optic nerves. Loss of vision could result from malfunction or damage to the optic nerves, depending on the type and location of the lesion. One or both eyes could experience vision impairment. Electrical signals are sent from retinal photoreceptor cells via the optic nerve to the brain's visual cortex.

Any damage to the optic nerve or its pathways has the potential to permanently harm the eyes and cause vision loss. One of the most frequent conditions that might harm the optic nerve is optic neuritis. The optic nerve is inflamed as a result of damage to or loss of myelin, the protective covering that covers it. Optic neuritis may be brought on by inflammation and myelin breakdown, according to researchers. The two nerves perform an essential task and converge at the optic chiasm.

Half of each side's nerve fibers cross over to the other side as the optic nerve splits in half. Injury and the removal of the nerve's protective covering both cause inflammation of the nerve. Glaucoma, optic neuritis, atrophy of the optic nerve, and optic disc drusen (ODD), among other conditions, are optic nerve disorders. Therapy options include corticosteroids, intravenous immune globulin (IVIG)/plasma exchange, vitamin B12 injection, and surgery, among others, depending on the degree and kind of disease identified.

Global Optic Nerve Disorders Treatment Market Overview

In 2019, 2.2 billion individuals worldwide experienced visual impairment or blindness, according to WHO. Out of these, cataracts, uncorrected refractive errors, glaucoma, corneal opacification, etc. are the main causes of vision impairment. One significant factor that contributes to the increase in fluid pressure in the eye, which worsens optic nerve damage, is glaucoma. It is frequently inherited by people, although it can also be brought on by an infection, an eye injury from chemicals, etc. Early detection and treatment options include eye drops, oral drugs, and operations like laser therapy.

Multiple sclerosis (MS), an autoimmune condition associated with the immune system attacking the body's healthy cells, is the primary cause of optic neuritis. Due to lowered immunity, MS is becoming more common in the aging population, while it can also be brought on by diabetes, smoking, infections, etc. Due to sedentary lifestyles, bad diets, lack of physical activity, etc., there is an increase in lifestyle disorders like diabetes, blood pressure, hypertension, etc., which further increases the likelihood that MS may cause ocular neuritis. The percentage of persons who need therapy for the disease is increasing as a result. Steroids are typically used to treat optic neuritis in order to prevent the condition's future progression.

Although there is no definitive cure for optic nerve illnesses, there is a lot of emphasis on preventing them and finding them early to avoid complications from medication, medications, and surgery. The increase in the elderly population and the growing awareness of the need for early diagnosis to stop the condition from getting worse has increased the demand for drugs and surgeries for treating optic nerve disorders, which has fueled the growth of the market for those treatments. However, the market's expansion is being hampered by potential side effects associated with the usage of medications for the treatment of optic nerve disorders like glaucoma, such as changing eye color, sunken eyes, itching, etc.

Global Optic Nerve Disorders Treatment Market Segmentation Analysis

The Global Optic Nerve Disorders Treatment Market is segmented on the basis of Type of Treatment, Type of Nerve Disorder, End User, And Geography.

Optic Nerve Disorders Treatment Market, By Type of Treatment

  • Eye Drops
  • Steroids
  • Intravenous immune Globulin/ Plasma Exchange
  • Vitamin B12 injection
  • Surgery

Based on Type of Treatment, The market is segmented into Eye Drops, Steroids, Intravenous immune globulin (IVIG)/Plasma Exchange, Vitamin B12 injection, and Surgery. Due to their simplicity of use, quick start of the action, and increased efficacy, eye drops are predicted to experience the largest growth during the estimated period.

  • Numerous common disorders are treated using eye drops. They can be used for tired, itchy eyes brought on by allergies. They might be recommended for bacterial or viral infections as well as other disorders like glaucoma. The entire therapeutic benefit of the drug might not be experienced when eye drops are not properly administered or used.

Optic Nerve Disorders Treatment Market, By Type of Nerve Disorder

  • Glaucoma
  • Optic neuritis
  • Others

Based on Type of Nerve Disorder, The market is segmented into Glaucoma, Optic neuritis, and Others. Due to a lack of knowledge about glaucoma and the rising elderly population, glaucoma is anticipated to rise the most during the anticipated time. due to an increase in open-angle glaucoma prevalence. Additionally, it is projected that an increase in the number of medications approved for the treatment of open-angle glaucoma will spur market expansion.

  • Additionally, the market for treatments for optic neuritis is anticipated to increase at the quickest rate throughout the anticipated period. This is ascribed to the rise in optic neuritis prevalence, the availability of reimbursement policies, and rising public awareness of multiple sclerosis driving the market expansion.

Optic Nerve Disorders Treatment Market, By End User

  • Hospitals
  • Ophthalmology Clinics
  • Ambulatory Surgical Centers

Based on End User, The market is segmented into Hospitals, Ophthalmology Clinics, and Ambulatory Surgical Centers. Due to the increased prevalence of optical disorders, accessibility to cutting-edge technology, and well-established healthcare infrastructure, the hospital segment is anticipated to grow the most throughout the anticipated period.

  • The availability of enhanced healthcare infrastructure, the rise in unmet healthcare needs, the rise in the prevalence of eye disease, and the spike in demand for medications to treat optic nerve disorders all point to high promise in unexplored, emerging markets. Additionally, the desire for better healthcare services, large government investments in enhancing the infrastructure for healthcare, and the growth of the medical tourism sector in emerging nations are all contributing to the significant growth of the healthcare sector in emerging economies.

Optic Nerve Disorders Treatment Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America

Based on Geography, The Global Optic Nerve Disorders Treatment Market is classified into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America. Due to its high illness prevalence, accessibility of reimbursement policies, and rising public awareness of multiple sclerosis and optic neuritis, the Asia Pacific area is anticipated to rise more than any other region throughout the forecasted period.

  • The market has grown in this area due to the presence of pharmaceutical companies there as well as the increasing purchasing power of populous countries like China and India. The market is expanding due to the aging population as well as the rising prevalence of diseases affecting the optic nerve, including glaucoma and optic neuritis.

Key Players

The "Global Optic Nerve Disorders Treatment Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as Bionure Farma S.L., Teva Pharmaceutical Industries Ltd, Santen Pharmaceutical Co. Ltd., Novartis AG, Pfizer Inc., Allergan plc., Aerie Pharmaceuticals Inc, Mallinckrodt Pharmaceuticals, Merck Sharp & Dohme Corp, and Bausch Health Companies, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

Key Developments

  • In February 2022, The results of a recent trial conducted by Horizon Therapeutics plc (Nasdaq: HZNP) showed that UPLIZNA medication effectively reduced the intensity of attacks in NMOSD patients.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the Global Optic Nerve Disorders Treatment Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in Global Optic Nerve Disorders Treatment Market gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data mining
  • 2.2 Secondary research
  • 2.3 Primary research
  • 2.4 Subject matter expert advice
  • 2.5 Quality check
  • 2.6 Final review
  • 2.7 Data triangulation
  • 2.8 Bottom-up approach
  • 2.9 Top-down approach
  • 2.10 Research flow
  • 2.11 Data sources

3 EXECUTIVE SUMMARY

  • 3.1 Overview
  • 3.2 Absolute $ Opportunity
  • 3.3 Market attractiveness
  • 3.4 Future Market Opportunities

4 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF TREATMENT

  • 5.1 Overview
  • 5.2 Eye Drops
  • 5.3 Steroids
  • 5.4 Intravenous immune Globulin/ Plasma Exchange
  • 5.5 Vitamin B12 injection
  • 5.6 Surgery

6 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY TYPE OF NREVE DISORDER

  • 6.1 Overview
  • 6.2 Glaucoma
  • 6.3 Optic neuritis
  • 6.4 Others

7 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Ophthalmology Clinics
  • 7.4 Ambulatory Surgical Centers

8 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL OPTIC NERVE DISORDERS TREATMENT MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies
  • 9.4 Company Regional Footprint
  • 9.5 Company Industry Footprint
  • 9.6 ACE Matrix

10 COMPANY PROFILES

  • 10.1 Bionure Farma S.L.
    • 10.1.1 Company Overview
    • 10.1.2 Company Insights
    • 10.1.3 Business Breakdown
    • 10.1.4 Product Benchmarking
    • 10.1.5 Key Developments
    • 10.1.6 Winning Imperatives
    • 10.1.7 Current Focus & Strategies
    • 10.1.8 Threat from Competition
    • 10.1.9 SWOT Analysis
  • 10.2 Teva Pharmaceutical Industries
    • 10.2.1 Company Overview
    • 10.2.2 Company Insights
    • 10.2.3 Business Breakdown
    • 10.2.4 Product Benchmarking
    • 10.2.5 Key Developments
    • 10.2.6 Winning Imperatives
    • 10.2.7 Current Focus & Strategies
    • 10.2.8 Threat from Competition
    • 10.2.9 SWOT Analysis
  • 10.3 Santen Pharmaceutical
    • 10.3.1 Company Overview
    • 10.3.2 Company Insights
    • 10.3.3 Business Breakdown
    • 10.3.4 Product Benchmarking
    • 10.3.5 Key Developments
    • 10.3.6 Winning Imperatives
    • 10.3.7 Current Focus & Strategies
    • 10.3.8 Threat from Competition
    • 10.3.9 SWOT Analysis
  • 10.4 Novartis AG
    • 10.4.1 Company Overview
    • 10.4.2 Company Insights
    • 10.4.3 Business Breakdown
    • 10.4.4 Product Benchmarking
    • 10.4.5 Key Developments
    • 10.4.6 Winning Imperatives
    • 10.4.7 Current Focus & Strategies
    • 10.4.8 Threat from Competition
    • 10.4.9 SWOT Analysis
  • 10.5 Pfizer
    • 10.5.1 Company Overview
    • 10.5.2 Company Insights
    • 10.5.3 Business Breakdown
    • 10.5.4 Product Benchmarking
    • 10.5.5 Key Developments
    • 10.5.6 Winning Imperatives
    • 10.5.7 Current Focus & Strategies
    • 10.5.8 Threat from Competition
    • 10.5.9 SWOT Analysis
  • 10.6 Allergan
    • 10.6.1 Company Overview
    • 10.6.2 Company Insights
    • 10.6.3 Business Breakdown
    • 10.6.4 Product Benchmarking
    • 10.6.5 Key Developments
    • 10.6.6 Winning Imperatives
    • 10.6.7 Current Focus & Strategies
    • 10.6.8 Threat from Competition
    • 10.6.9 SWOT Analysis
  • 10.7 Aerie Pharmaceuticals
    • 10.7.1 Company Overview
    • 10.7.2 Company Insights
    • 10.7.3 Business Breakdown
    • 10.7.4 Product Benchmarking
    • 10.7.5 Key Developments
    • 10.7.6 Winning Imperatives
    • 10.7.7 Current Focus & Strategies
    • 10.7.8 Threat from Competition
    • 10.7.9 SWOT Analysis
  • 10.8 Mallinckrodt Pharmaceuticals
    • 10.8.1 Company Overview
    • 10.8.2 Company Insights
    • 10.8.3 Business Breakdown
    • 10.8.4 Product Benchmarking
    • 10.8.5 Key Developments
    • 10.8.6 Winning Imperatives
    • 10.8.7 Current Focus & Strategies
    • 10.8.8 Threat from Competition
    • 10.8.9 SWOT Analysis
  • 10.9 Merck Sharp & Dohme Corp
    • 10.9.1 Company Overview
    • 10.9.2 Company Insights
    • 10.9.3 Business Breakdown
    • 10.9.4 Product Benchmarking
    • 10.9.5 Key Developments
    • 10.9.6 Winning Imperatives
    • 10.9.7 Current Focus & Strategies
    • 10.9.8 Threat from Competition
    • 10.9.9 SWOT Analysis
  • 10.10 Bausch Health Companies
    • 10.10.1 Company Overview
    • 10.10.2 Company Insights
    • 10.10.3 Business Breakdown
    • 10.10.4 Product Benchmarking
    • 10.10.5 Key Developments
    • 10.10.6 Winning Imperatives
    • 10.10.7 Current Focus & Strategies
    • 10.10.8 Threat from Competition
    • 10.10.9 SWOT Analysis

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 APPENDIX

  • 12.1 Related Research